1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
CPRIT Seed Grants for Product Development Research is sponsored by Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT offers direct cash grants for cancer research and commercialization for companies based in Texas. This supports early R&D and helps bring innovations to market, specifically in the area of cancer diagnostics and treatment.
Get alerted about grants like this
Get emailed when new opportunities from “Cancer Prevention and Research Institute of Texas (CPRIT)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
CPRIT’s Product Development Research Program funds projects at Texas-based companies developing novel products or services intended to benefit cancer patients. Groundbreaking science is most valuable when it is translated into cancer drugs, diagnostics, and therapies that are available to all Texans. Product development activities convert novel laboratory findings into a safe and reliable product available to treat cancer patients.
CPRIT supports projects that accelerate the development of promising research discoveries through the crucial early stages of regulatory development. Summaries of the four Requests for Application are listed below: ### Texas Therapeutics Company RFA Funding available through this RFA supports the ongoing research and development of innovative products, services, and infrastructure with significant potential impact on patient care.
Generally, at this stage, the company has identified and characterized a lead compound; demonstrated efficacy in multiple translationally relevant animal models; completed pilot/dose ranging toxicology studies; determined the feasibility of a scalable, GMP compliant manufacturing process, including release assays; and identified a prototype formulation suitable for further development.
The applicant is typically within one year from filing an IND/IDE or already in Phase 1.
With appropriate justification, companies may use CPRIT funds to support the following: • Studies that establish preclinical proof of concept (safety and efficacy) • CMC/manufacturing development • GLP safety studies to support INDs • Phase 1 in humans to establish safety and a recommended dose for phase 2 • Phase 2 studies to determine safety and efficacy in initial targeted patient population ### Texas Device and Diagnostics Company RFA Funding available through this RFA supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer.
Relevant areas include: • Devices and assays for cancer detection, diagnosis, prognosis, monitoring, treatment and prediction of response or resistance to treatment • Markers for cancer prevention and control, companion diagnostic to a therapy • Development of diagnostic tests to distinguish high-risk early lesions Generally, at the time that an applicant applies to CPRIT pursuant to this RFA, the company has developed a commercial prototype of the device or a pictorial representation of the functional components/elements of the device.
With respect to diagnostics, the company has developed assays that work on human samples and whose importance is well justified for development into clinical assays. The applicant should be working toward submitting an Investigational Device Exemption (IDE) or a 510(k) or Premarketing Approval (PMA) and is typically within one year from filing an IDE (or later stage work.)
Potential applicants that are not at or near this stage of product development should consider applying for a Texas Seed Company Award. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.
### Texas New Technologies Company RFA Funding available through this RFA supports the ongoing research and development of new and emerging technologies for the detection, diagnosis, prognosis, monitoring, or treatment of cancer. CPRIT created this RFA to fund new and emerging technology projects that do not easily fit into any of the three other CPRIT Product Development Research RFAs.
Proposals may include, but are not limited to, bioinformatics, artificial intelligence, production of radionuclides or their precursors, manufacture of cell-based therapies, processes to improve the quality of the samples used for cancer research or clinical care, and biomanufacturing of therapeutics.
With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.
### Texas Seed Company RFA Funding available through this RFA supports company formation, as well as early research and development of novel oncology therapeutics, devices, treatment-oriented information technology products, diagnostics, or tools.
The objective of the SEED Award program is to start with an interesting technology and to progress it toward a commercially viable business opportunity, i.e., make it more attractive to private funding agents.
Typically, applicants have completed the following activities: • Identified a novel therapeutic, diagnostic technology, or clinical tool and shown a biological effect • Conducted preliminary safety and toxicology testing (in the case of therapeutic agents) • Shown the product can be manufactured at small scale or as a prototype • Assessed the business opportunity and organized a business plan that begins to address key issues (clinical utility, target market, financial plan, IP strategy, technical challenges, etc.) and lays out a preliminary development plan (formulation, toxicology, scale up, IND-enabling studies, phase 1 clinical trials, regulatory pathway, etc.).
## PDR Review Process FAQ **Q:What is CPRIT’s Product Development Review Process? ** **A:**This is the current Product Development review process: * Applicants will submit a preliminary application comprised of a 2-page executive summary, a slide deck of up to 16 slides providing an overview of the scientific basis for the proposed project, and a 1-page explanation of the project’s aims and requested budget.
* The company may submit the preliminary application at any time while the portal is open. * The Product Development Review Council (PDRC) will judge the application for scientific merit and consider whether the company presents a compelling idea for CPRIT investment. * If the PDRC sees sufficient scientific merit and a persuasive premise for the project, it will invite the applicant to submit a full application.
* CPRIT will notify the applicant of the PDRC’s decision within 3 – 5 weeks of submission. The review process will end for those applicants not invited to submit a full application. Applicants not successful in the preliminary or the full application review process will have limited opportunities to resubmit an application.
* For applicants invited to submit a full application, CPRIT will offer a specific date and time for the applicant to present their proposal to the review panel via zoom. **Q: Is the CPRIT award a grant or some other type of investment? ** **A:** CPRIT awards grants to fund product development projects through a competitive, peer reviewed process.
Although these are grants, CPRIT provides all funds via a contract specifying agreed-upon goals and objectives and requires, among other terms, matching funds contributed by the company and an agreement to share revenues via royalty payments, equity, or some other arrangement in the mutual interest of the state and the company. **Q: How long are the awards?
** **A:**All CPRIT RFAs support three-year projects in Texas, with an opportunity to extend the duration of contract to fully expend awarded funds. **Q: How much will CPRIT award for a project? ** **A:**Except for Seed Company Awards, which CPRIT caps at $3 million per project, applicants may request any amount of funding appropriate to the work proposed and the development stage.
All requested funds must be well justified. CPRIT will evaluate requests for a significant amount of funding more stringently to ensure that the project is of demonstrable importance in terms of innovation and impact as not to displace other worthy investments. CPRIT has approximately $70 million per fiscal year available for investment in product development awards.
CPRIT reserves the right to close the application portal until the next fiscal year if CPRIT exhausts its annual allocation for product development awards. **Q: Can a company located outside of Texas apply for a CPRIT product development award? ** **A:** CPRIT encourages companies located outside of Texas to apply to one of the four RFAs.
As a condition of receiving the CPRIT grant, the company must meaningfully commit to locating in Texas and maintaining its business presence within the state. CPRIT developed Texas location criteria that all CPRIT-funded companies use to signal commitment to Texas and to developing the state’s life science ecosystem. CPRIT takes the company’s obligation to Texas seriously.
Be aware that Texas taxpayer-supported general obligation bonds fund all Product Development awards. **Do not apply if it is not your intention to locate and maintain your business in Texas. ** Fraud, deception, or other bad faith actions to evade the obligation to establish and maintain status as a Texas company will result in termination, repayment, and any other remedy available by law or contract.
Because companies from outside the state are eligible to apply for any product development award, CPRIT has retired the Relocation Company RFA.
According to the current listing, eligibility includes: Small businesses focused on cancer research and commercialization, located in Texas. Confirm the full requirements in the official notice before applying.
CPRIT Seed Grants for Product Development Research is funded by Cancer Prevention and Research Institute of Texas (CPRIT). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Texas. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Individual Investigator Research Awards for Clinical Trials (IIRACT) is a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) that funds clinical trials research aimed at preventing and curing cancer in Texas. The program supports Texas-based entities conducting clinical trials across cancer types, with applications accepted through May 20, 2026 (RRCTA mechanism) and with an April 28, 2026 deadline for individual investigator awards. Eligible applicants include nonprofit institutions and private companies based in Texas. CPRIT now supports ORCID IDs in applicant profiles to streamline the application process.
Recruitment of First-Time, Tenure-Track Faculty Members (RFT) is sponsored by Cancer Prevention and Research Institute of Texas (CPRIT). This program supports very promising emerging investigators pursuing their first faculty appointment in Texas, who have the potential to make outstanding contributions to the field of cancer research. CPRIT is a state agency that funds cancer research in Texas.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
The FY2026 COPS School Violence Prevention Program offers up to $500,000 per award across roughly 200 grants, with a 25% match and a $100,000 microgrant lane for rural and tribal schools. But the statute limits it to physical security and law enforcement coordination — not mental health. Here is what SVPP actually funds, who can apply, and how to build a competitive application before August 4, 2026.
Read articleOn June 24, 2026, FEMA released more than $1.5 billion across the Homeland Security Grant Program, a $300 million Nonprofit Security Grant Program, and six infrastructure-protection programs — all with an application window closing around July 24. This is the definitive breakdown: how SHSP, UASI, Operation Stonegarden, and the transit, port, Amtrak, and intercity-bus grants differ, what the new FY2026 priorities signal, why almost none of the money comes to you directly from FEMA, and the strategy for competing through your State Administrative Agency.
Read articleBEAD put tens of billions into the ground, but there aren't enough fiber technicians to install it. In 2026, states are opening a second funding stream — workforce grants for community colleges, nonprofits, and training providers. Here is where the money is, who can win it, and how to position a broadband-training proposal.
Read article